5-HT$_3$ Receptors: A Potential Therapeutic Target for Epilepsy

Hongyan Zhao$^{1,2}$, Yang Lin$^1$*, Shurui Chen$^3$, Xin Li$^1$* and Hongliang Huo$^{2,*}$

$^1$Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun 130041, P.R. China; $^2$School of Life Science Northeast Normal University, Changchun, Jilin 130024, P.R. China; $^3$Jinzhou Medical University, Jinzhou 121000, P.R. China

Abstract: Background: Epilepsy is a syndrome of brain dysfunction caused by spontaneous, abnormal discharge. Many anti-epileptic drugs have developed in past decades. 5-HT is an important neurotransmitter in the central and peripheral nervous system of the human body which is involved in a number of physiological activities, such as sensation, movement, and behavior. 5-HT subtype have been divided into seven sub-groups from 5-HT$_1$ to 5-HT$_7$. However, the role of 5-HT$_3$ receptor on epilepsy is unclear. Therefore, in this article, the possible role of 5-HT$_3$ receptor on epilepsy was systematically reviewed.

Methods: Data were collected from Web of Science, Medline, Pubmed, Scopus, through searching of these keywords: “5-HT$_3$” and “epilepsy”.

Results: An increasing number of studies have shown that the activation of the 5-HT$_3$ receptor can inhibit epileptic seizures, while inhibition of the 5-HT$_3$ receptor can promote spike waves.

Conclusion: In this review, we discuss the relationship between the 5HT$_3$ receptor and epilepsy; this review may provide a new insight for clinical application of epilepsy treatment.

Keywords: 5-HT$_3$ receptor, epilepsy, antagonists, Neuron, GABA, NMDA.

1. INTRODUCTION

Epilepsy is a chronic disorder of the brain caused by sudden abnormal discharge of neurons. It is characterized by persistent changes in the brain that can produce seizures. To date, the disease affects more than 60 million people worldwide [1], making one of the most common neurological diseases across the globe. The risk factors for epilepsy include changes in age and geographical location, as well as congenital, developmental, and hereditary factors. Epilepsy typically emerges in childhood, adolescence, or early adulthood. It is the second most common diseases in the nervous system [2]. According to an epidemiological survey, the general population prevalence rate of epilepsy is five per thousand to seven per thousand yearly. There are many causes of epilepsy, though the fundamental reason is understood to be abnormal synchronous discharge secondary to the neural network. Epilepsy is caused by abnormal ion conduction or other changes in neural membrane, or excitatory and inhibitory imbalance [3]. Studies have also indicated a number of complications that can arise at any time during the progression of epilepsy [4].

Countless researchers have proposed a wide variety of treatment for epilepsy, including traditional drug therapy having gradually extended to cell transplantation, nerve stimulation, gene therapy, and other treatments. As of now, there is no cure, surgery is possible, but introduces a great deal of risk [5]. However, present antiepileptic drugs provide only partial control of seizures [6]. Existed treatments methods are mainly based on managing symptoms that do not affect the underlying disease process, and are often accompanied by severe side effects. Arguably, the ineffectiveness of these treatments mainly is due to the lack of identified target [7]. Frequent and long-term seizures, and subsequently a series of psychological changes not only impact quality of life in epileptic patients, but place a burden upon his or her family and community. In this review, we will focus on further exploration of the pathogenesis of epilepsy in terms of identifying novel drugs and therapeutic targets.

In 1957, Bonnycastle, et al. first asserted that there is a relationship between 5-HT and epilepsy inhibition due to the fact that many anti-epileptic drugs increase the concentration of 5-HT in the brain [8]. Indeed, a wealth of evidence has shown that changes in the serotonin (5-HT) neurotransmitter may be an underlying mechanism of the disease [9, 10].

Serotonin plays a key role in a wide range of biological processes, in fact. Its actions are 5-HT mediated by a family of G-protein-coupled receptors referred to 5-HT$_1$, 5-HT$_2$, 5-HT$_3$, 5-HT$_4$, 5-HT$_5$, 5-HT$_6$, and 5-HT$_7$. The 5-HT receptors are highly expressed in the brain, suggesting that they play a key role in the nervous system. These compounds are often utilized in the treatment of anxiety, epilepsy, obsessive-compulsive disorder, schizophrenia, sleep disorders, and
other diseases [11]. Pentylenetetrazole (PTZ) is mainly used for acute infectious diseases, anaesthetic, and barbiturate poisoning induced respiratory depression, acute circulatory failure. Research shows that 5-HT3 receptor excitement and antagonism can effectively change the PTZ induced clonic convulsion threshold in mice, implying that the 5-HT3 receptor is involved in brain excitability and seizure discharge expression. On the contrary, selective 5-HT3 receptor activity is enhanced under a high seizure threshold, demonstrating that the 5-HT3 receptor may be useful in terms of treating seizures [10, 12].

In effort to better understand the relationship between epilepsy and the 5-HT3 receptor, we carefully reviewed the extant research on epilepsy animal modeling, 5-HT receptors subunit distribution, and 5-HT3 receptors as ligand gated ion channels; we also explored previous studies on the receptor activation, the relationship between the antagonist agent, and epilepsy pathogenesis establishment via gene knockout models. Finally, we compare the pathogenesis of epilepsy and depression to build an analogy that we hope will represent a new target for 5-HT3 electrophysiological epilepsy treatment.

2. EPILEPSY MODEL

An appropriate epilepsy model is a crucial part of understanding the pathophysiology of epilepsy and the efficacy of anti-epileptic drugs. Epilepsy models can be in vivo or in vitro. The former includes the neuron model and the brain slice model, and are mainly used for drug screening and investigating anti-epileptic drug dose effect relationships. The latter include the acute epilepsy model, chronic epilepsy model, genetic epilepsy model, and resistant epilepsy model, and are utilized to represent different types of human epilepsy.

2.1. In Vitro Model

2.1.1. Neuron Model

The neuron is the fundamental material exploited to establish any in vitro epilepsy. Researchers typically mouse cerebellar granule cells, cells from the cerebral cortex, and hippocampal neurons as the basis for the studies. The excitatory glutamate model is a relatively mature epilepsy model than can be used to induce a seizure like discharge that may be related to the excitatory NMDA receptor, which induces Ca2+ influx and increase the concentration of Ca2+ [13].

2.2. In Vivo Model

2.2.1. Acute Epilepsy Model

The most significant existing acute epilepsy model is the maximum electric shock (MES) model, which is favored for ion channel drug research. Its use many results in certain drugs being selected for further research (e.g., aminocaproic acid, tiagabine etc.), while others with anti-epilepsy effect are neglected [14], therefore people focus their attention on chronic epilepsy.

2.2.2. Chronic Epilepsy

The chronic epilepsy model, kindling model, continuous epilepsy model and spontaneous epilepsy model have been applied in studies on the pathophysiology of chronic epilepsy [15]. The kindling model uses repeated electrical and chemical stimulation of the thalamus, hippocampus, and other regions to show progressive epileptic activity in the EEG.

2.2.3. Genetic Epilepsy Model

Researchers have used in vivo genetic models to investigate generalized seizures to find that the mechanism of the disease may be related to the degree of reticular nucleus activity, the characteristics of the membrane and state of the ion channel, the activity of proteins and enzymes, genetic and chromosomal mutations, and other factors [16].

2.2.4. Resistant Epilepsy Model

The resistant epilepsy model has been used in studies on the treatment of intractable epilepsy and, as the name suggests, epilepsy resistance. These models include the lamotrigine-resistant kindled rat, the 6 Hz psychomotor seizure model of partial epilepsy model, and post-status epileptic models of temporal lobe epilepsy model [17].

Although, epilepsy model cannot imitate the whole process of the development of epilepsy in humans, the epilepsy model established provides a good basis for the pathogenesis of epilepsy research. At the same time, people can also through this model for screening of anti-epilepsy drugs. This also may provide a more in-depth understanding of the basis for the occurrence and development of epilepsy.

3. DISTRIBUTION AND FUNCTION OF 5-HT RECEPTOR SUBFAMILY

5-HT is a neurotransmitter which functions in the central nervous system (CNS) and peripheral nervous system (PNS) as well as in non-neural tissues (e.g., those in the gastrointestinal, endocrine and cardiovascular systems). It also interacts with membrane receptor. It has many functions, including regulating emotion, appetite, sensations, cognition, pain, sleep, gastrointestinal motility, visceral sensitivity, and more [18]. There are seven types of 5HT receptors (5-HT1 to 5-HT7) with various structure, conduction, and operation characteristics. The distribution and function of each of these receptors are shown in (Table 1).

5-HT1 receptors are further divided into five categories: 5-HT1A, 5-HT1B, 5-HT1E, 5-HT1D, and 5-HT1F. The 5-HT1A receptor is mainly distributed in the CNS, and in human is located on the chromosome 5q11.2-q13 [19]. 5-HT1A knockout mice showed a reduced toxicity of the low-temperature response, which was thought to be mediated by the 5-HT1A receptor in the hypothalamus [20]. The human 5-HT7B receptor is located on chromosome 6q13; it is a G protein-coupled receptor which may promote the release of calcium [21, 22]. 5-HT7B knockout mice exhibit aggressive behavior, as well as increase in the regulation of impulsive behavior (which is not an increase in aggression itself) [23]. Any increase in 5-HT7B receptors is mainly regulated by short-term and long-term memory [24, 25]. 5-HT7D receptor has 374-377 amino acids without splice variants, and is associated with anorexia [26]. 5-HT7E receptor has been identified in the human frontal cortex on chromosome 6q14-q15, but their widespread distribution has not been confirmed [27,
Table 1. Distribution and function of 5HT receptor subfamily.

| 5-HT1 | 5-HT2 | 5-HT3 | 5-HT4 | 5-HT5 | 5-HT6 | 5-HT7 |
|-------|-------|-------|-------|-------|-------|-------|
| Central nervous system | Central nervous system | Sensory vagus nerve, intestine, sea horse CA1 area, amygdala, substantia nigra, brainstem | Adrenal cortex | Cerebellar cortex hippocampus, only CA1 area of the hippocampus | Brain regions such as striatum, limbic brain, and cerebral cortex | Pineal gland and hypothalamus |
| Depression, anxiety, insomnia | Nervous disorders | Epilepsy | Bowel movement | Migraine | Understanding disorders, memory disorders, nervous division | Sleep, cognition, body temperature regulation, affective disorder, hormone secretion |

28]; the receptors are not expressed in rats or mice [29]. The 5-HT1F receptor gene is located on chromosome 3p11. It is speculated that the receptor may be a prime target for antimigraine drugs [30].

5-HT2 is divided into three categories: 5-HT2A, 5-HT2B, and 5-HT2C. The 5-HT2A receptor gene is located on human chromosome 13q14–q21, and is encoded by 471 amino acids in the NPC mouse [31-34]. It is known to participate in the regulation of long-term memory and short-term memory [24, 25]. The expression of the 5-HT2B receptor has a significant impact on the cardiovascular system in mice [35]. The 5-HT2C receptor gene is located on human chromosome 4q24 with 458-5-HT2C; interestingly 460 amino acid receptor gene knockout mice are severely obese [36].

5-HT3 receptors are divided into two classes: 5-HT3A and 5-HT3B, which are the only ligand gated ion channel receptors in the 5-HT receptor family [37]. So far, it has been confirmed that there are two genes encoding the 5-HT3 receptor. The 5-HT3A receptor subunit contains 487 amino acids and, cysteine with high levels of Cys loop ligand gated ion channels (e.g., nicotine, GABA, glycine receptor subunit II) 5-HT3B is a 441 amino acid encoding receptor [38], with a pentamer subunit that wraps around its composition and a central channel single subunit composed of a large extracellular N-terminal domain (ECD) [39], four trans membrane domain (M1-M4), and an extracellular C-terminal [40]; spiral portions of the amino acids in its large cell cycle assist ion permeation [41].

The 5-HT4 receptor is located on chromosome 5q31-33. 5-HT4A and 5-HT4B are present in the bladder and kidney, while 5-HT4C and 5-HT4D are present in the brain and intestine [42]. 5-HT3 includes 5-HT4A and 5-HT4B. The 5-HT4A receptor has 357 amino acids located on the human chromosome 7q36.1 [43]. It has been reported that 5-HT4A antagonists have antidepressant/anti-psychotic drug characteristics in animal models (Garcia-Ladona et al., unpublished). The 5-HT4B receptor gene exists in the human chromosome 2q11-q13 and is not an encoded functional protein. 5-HT6 is located in the chromosomes region of 1p35-p36, and is an antagonist on learning and memory function [44]. 5-HT7 receptors are located on the human chromosome 10q21-q24 and have been shown to play a role in sleep, circadian rhythms, and mood [45].

4. 5-HT INVOLVED IN THE PATHOGENESIS OF EPILEPSY

5-HT, as discussed above, is a neurotransmitter that functions in the CNS and PNS as well as several non-neuronal tissues that is involved in membrane receptor interaction [46]. The 5-HT system is involved in the pathogenesis of epilepsy and neuropathic pain. To be precise, 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, and 5-HT7 receptors are involved in the occurrence and maintenance of epilepsy and in altered susceptibility to seizures [47-49]. 5-HT deficiency is the primary cause of seizures, and certain anti-epileptic drugs work by increasing the level of extracellular 5-HT receptors to produce anti-epileptic effect [50]. Lack of 5-HT2A receptors significantly increases the risk of seizure. The receptor may directly or indirectly control neuronal excitability throughout several network structures by interacting with the monoamine neurotransmitters GABA and glutamate [51].

The cerebral cortex nerve metabotropic and ionotropic 5-HT3 receptor, 5-HT2 (5-HT2rs and 5-HT2rs), is the main medium of excitatory 5-HT. The role of these receptors is related to intrinsic neuronal and synaptic excitability levels [52]. Studies have shown that activation of the 5-HT3 receptor through SR57227 is related to PTZ-induced seizures and possibly related to hippocampal GABA activity [53]. Notable, among the 5-HT receptor family, only 5-HT3 receptors are ligand gated ion channels that can directly or indirectly act by changing cell ion conductance or concentration leading to neuronal depolarization. It is not surprising, then, that any major shift in 5-HT receptors in the body is related to the induction of epilepsy [3].

4.1. 5-HT3 Receptor Ligand Gated Ion Channel

5-HT3 receptors are ligand gated ion channel is located on the cell membrane which cause neuronal depolarization by changing the sodium ion, potassium, and calcium ion transmembrane [54, 55]. 5-HT3 receptors are distributed in the entorhinal cortex, hippocampus CA1 area, amygdala, substantia nigra, and brainstem, and have strong expression.
Recent studies have shown that the entorhinal cortex, hippocampus CA1 area, amygdala, substantia nigra, and brainstem represent a common pathway in epilepsy pathogenesis. As opposed to the 5-HT\textsubscript{2}C receptor, as mentioned above, the 5-HT\textsubscript{3} receptor is a ligand gated ion channel receptor which mediates excitatory effect; accordingly, when 5-HT is combined with the 5-HT\textsubscript{3} receptor present in these regions into the target cells with high specificity and high affinity with the original combination, they can open non-selective cation channels, impact Na\textsuperscript{+}, Ca\textsuperscript{2+}, and K\textsuperscript{-} influx and efflux, and produce an inward current. Thus, via postsynaptic depolarization, the voltage gated calcium channel is opened to produce excitatory postsynaptic potential and the epileptic impulses are transmitted and strengthened, resulting in epilepsy. This is consistent with the mechanism of glutamate induced epilepsy [56]. Further as a function of the cell, the calcium receptor is very important in cell signal transduction. At the same time, the concentration of chloride ions in the cell can change the GABA mediated depolarization leading to seizures [57]. In short, the 5-HT\textsubscript{3} receptor most certainly plays a crucial role in the control of epilepsy.

### 4.2. 5-HT\textsubscript{3} Receptor Antagonists and Agonists

5-HT\textsubscript{3} receptors in the CNS, brainstem nuclei, end zone, nuclear solitary and spinal cord are relatively high, in the cortex, hippocampus, and amygdala [11b, 58]. In vitro experiments have shown that blocking the 5-HT\textsubscript{3} receptor in mice causes significantly delayed epileptic seizures induced in vivo, and may even stop them completely [52]. The antiepileptic activity of selective 5-HT\textsubscript{3} reuptake inhibitor has also been reported [59]. Ondansetron is a highly selective 5-HT\textsubscript{3} receptor antagonist, that has proven effective in treating several diseases such as anxiety, itching, refractory chronic diarrhea, irritable bowel syndrome, and epilepsy [60], and researchers have demonstrated its anticonvulsant potential in experimental seizure models as well [61, 62]. Other experiments have shown that adding the inhibitor causes the seizure rate of mice to increase [63]. According to shock experiments, the protective effect of Ondansetron may be due to the cation influx of change Na\textsuperscript{+}, Ca\textsuperscript{2+}, or K\textsuperscript{-} leading to neuronal depolarization inhibition [61]. In a mouse model Ondansetron showed anticonvulsant effect against epileptic seizures in accordance with results obtained by Mohanty and Balakrishnan et al. [62].

PTZ, a c-aminobutyric acid (GABA) receptor antagonist, has been widely used in animal epilepsy models [64, 65]. Evidence suggests that the 5-HT\textsubscript{3} receptor can also be expressed through GABA in the hippocampus and cortex neurons [66, 67]. PTZ-induced seizure test have shown that in the present of PTZ [68], Ondansetron does not inhibit epileptic seizures. There also is neurochemical evidence that PTZ blocking factors are comprised mainly of the inhibition of GABA-mediated inhibitory effect. N-methyl-D-aspartate receptor and GABA participate in PTZ-induced seizure initiation and receptor propagation [63].

5-HT\textsubscript{3} is comprised of ligand gated ion channels and can regulate the activity of other neurotransmitters, such as norepinephrine, GABA, glycine, and dopamine and acetylcholine agents [54, 69-71]. The 5HT\textsubscript{3} receptor antagonist works as an inverse agonist benzodiazepine agent in GABA receptors and as a GABA inhibiting agent [70, 72]. Ondansetron application has been shown to reverse the inhibition of GABA in rats in the anterior meningeal [73]. The exact mechanism of Ondansetron is unknown, but it may be related to enhance cholinergic brain functions as 5-HT\textsubscript{3} receptor heterogeneity modulates the activity of several neurotransmitters in the amygdala, cholinergic hippocampus, and glutamatergic system [74, 75]. SR57227 is a potent and selective agonist at the 5HT\textsubscript{3} receptor, with high selectivity over other serotonin receptor subtypes and good blood-brain barrier penetration [76]. Seizure latency was significantly increased in SR57227, in a manner significantly dependent on 5HT\textsubscript{3} receptor addition [10]. In an experimental group of mouse models with the receptor activator, the death rate of mice was also significantly decreased due to add SR57227 [10]. Altogether, the results described above have well established that the 5-HT\textsubscript{3} receptor is an important potential target for epilepsy treatment [10]. In many organisms, 5-HT and GABA is maintaining the balance of the nervous system. The levels of them are closely linked with neurophysiology, behavior, pathology, disease diagnosis and control [77]. Studies have shown that 5-HT can enhance GABA mediated inhibitory postsynaptic potential in rat hippocampal CA1 region [78]. Among the numerous types of 5-HT, the regulatory effect of 5-HT\textsubscript{3} receptor subtype on GABA was the most clear. 5-HT\textsubscript{3} receptors exist in layer I GABAergic neurons, a cortical level without pyramidal cells, indicates that 5-HT receptors can regulate the apical dendrites of input to pyramidal neurons in prefrontal cortex via 5-HT\textsubscript{3} receptors located in GABAergic interneurons [67]. In addition, activation of the 5-HT\textsubscript{3} receptors in the GABA neurons in the cortical 5-HT is able to inhibit the cholinergic function [78].

### 4.3 Gene Knockout Model

“Gene knockout” refers to a genetic engineering technology where for a known sequence (but of unknown function) the gene is altered to block a portion of its function, then, the biological impact is analyzed to assess the comprehensive biological function of the target gene. In recent years, gene knockout has been applied in many fields. For example, in effort to determine the CNTNAP2 gene function, it was knockout in a mouse model to find that it affects learning and memory function through its impact on the nervous system [79]. In another study, researchers attempted to establish Nox1y/-, Nox2y/-, or NOX4 genes as novel antiangiogenesis therapy targets, using gene knockout technology. They found that the Nox4-/- gene in a mouse tumor model showed significant decrease in vessel formation density compared to the control, suggesting that NOX4 gene may be a new target in the treatment of tumor valuable antiangiogenesis target [80].

Gene knockout mouse models have also been utilized to examine the relationship between 5-HT receptor subtypes and epilepsy. Mutant mice lacking the 5-HT\textsubscript{2} receptor subtype have been found to suffer death due to seizures [81], and 5-HT\textsubscript{A} receptor gene knockout mice show reduction in seizure threshold and higher mortality [82]. 5-HT\textsubscript{A} receptor single gene knockout mice have shown significant spatial memory impairment, suggesting that the 5-HT\textsubscript{A} receptor subtype mediates spatial learning and memory [83].
Other studies on the 5-HT receptor gene, have investigated liver injury marker 5-HT transporter function by knocking out SERT (+/-) in mice and observing them in comparison to wild-type mice; 5-HT receptor knockout mice liver steatosis was significantly decreased, indicating that the gene was indeed missing, which is a key factor in fatty liver development [84].

In order to prove that the deficiency in brain 5-HT synthesis will affect animal behavior changes and neuroendocrine responses, then knock in mice tryptophan hydroxylase 2 gene and found that mice showed increased basal metabolism, reduce anxiety but strikingly increased conditioned fear responses, which indicates that the content of 5-HT in the brain does have an impact on the changes of animal behavior and neuroendocrine responses [85].

Engrailed 2 (EN2) as a possible autism susceptibility gene, EN2 knockout mice (EN2 -/-) 5-HT content decreased significantly in one and three months old mice, at the same time, the mice showed subtle cerebellar pathology change and tyrosine hydroxylase levels reduce [86]. Because knockout studies have confirmed the exact location of the 5-HT3 receptor gene, it is highly likely that further knockout studies can be utilized to confirm the incidence rate of epilepsy in mouse models.

4.4. Epilepsy and Depression

The coexistence of epilepsy and depression is an interesting (and potentially dangerous) psychiatric phenomenon. Epilepsy patients suffer a suicide rate four times higher than that of healthy people [87]. Treatment must not be limited to epilepsy itself, but must also be targeted toward neural, cognitive, and psychiatric complications which commonly coexist with epilepsy. Depression, for example, is very commonly present with epilepsy [88].

Norepinephrine and 5-HT deficiency have been shown to increase the incidence of certain forms of epilepsy and depression. Epidemiological investigation has confirmed the coexistence of these diseases, but also indicates that they are often difficult to read. Depression may actually be inextricably linked to epilepsy; interestingly, antidepressant drugs have anticonvulsant properties and anti-epileptic drugs can be used to treat affective disorders [89]. Research suggests that the 5-HT3 receptor antagonist can increase single amine neurotransmitter release, which reflects a mechanism related to depression treatment [90]. These studies on 5-HT3 and depression may provide a valuable reference for future research on novel epilepsy treatments.

5. FUTURE RESEARCH DIRECTION

The treatment of epilepsy is a complex and lengthy process characterized by an unfortunate amount of uncertainty. They have indeed been many significant contributions to the literature in terms of innovative treatment techniques, but much work remains to be done. 5-HT, an important neurotransmitter in the CNS and PNS, is a receptor closely related to the onset and pathogenesis of epilepsy, a rather large quantity of research results support this relation. That said these results were established based on animal models, and we cannot be entirely sure whether there are identical or similar mechanisms in the human body. Certainly though, the extant research discussed above represents an important future direction for further research on the 5-HT receptor as a novel target for epilepsy treatment.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

This work was funded by Jilin Provincial Science and Technology Department Project (No.20150520035JH) and Bethune Plan Project of Jilin University (No.2015427).

REFERENCES

[1] Wang, G.X.; Wang, D.W.; Liu, Y.; Ma, Y.H. Intraocular epilepsy and the P-glycoprotein hypothesis. Int. J. Neurosci., 2016, 126(5), 385-392. [http://dx.doi.org/10.3109/00207454.2015.1036710] [PMID: 26000919]
[2] Celli, R.; Santolini, I.; Guiducci, M.; van Luijtelaar, G.; Parisi, P.; Striano, P.; Gradini, R.; Battaglia, G.; Ngomba, R.T.; Nicoletti, F. The α2δ subunit and absence epilepsy: Beyond calcium channels? Curr. Neuropharmacol., 2017, 15(6), 918-925.
[3] Manjarrez-Marmolejo, J.; Franco-Pérez, J. Gap junction blockers: An overview of their effects on induced seizures in animal models. Curr. Neuropharmacol., 2016, 14(7), 759-71.
[4] Armstrong, T.S.; Kanusky, J.T.; Gilbert, M.R. Seizure the moment to learn about epilepsy in people with cancer. Clin. J. Oncol. Nurs., 2003, 7(2), 163-169. [http://dx.doi.org/10.1188/03.CJON.163-169] [PMID: 12696212]
[5] Erturk, O.; Ozkara, C.; Yalcinkaya, C.; Dervent, A.; Yeni, S.N.; Demiribilek, V.; Unver, O.; Uysal, S.; Ozurt, E.; Uzan, M. Epilepsy surgery in children with lesional partial seizures. Turk Neurosurg., 2015, 25(6), 900-904. [PMID: 26617140]
[6] Nazarolou, M. TRPV1 channel: A potential drug target for treating epilepsy. Curr. Neuropharmacol., 2015, 13(2), 239-247. [http://dx.doi.org/10.2174/1570159X13666150216222543] [PMID: 26411767]
[7] Srivastava, A.; Dixit, A.B.; Banerjee, J.; Tripathi, M.; Sarat Chandra, P. Role of inflammation and its miRNA based regulation in epilepsy: Implications for therapy. Clin. Chim. Acta, 2016, 452, 1-9. [http://dx.doi.org/10.1016/j.cca.2015.10.023] [PMID: 26506013]
[8] Bonnycastle, D.D.; Giarman, N.J.; Paasonen, M.K. Anticonvulsant compounds and 5-hydroxytryptamine in rat brain. Br. J. Pharmacol. Chemother., 1957, 12(2), 228-231. [http://dx.doi.org/10.1111/j.1476-5381.1957.tb00125.x] [PMID: 13446387]
[9] Maia, G.H.; Soares, J.J.; Andrade, P.A.; Leite, J.F.; Luz, L.L.; Andrade, J.P.; Lukoyanova, N.V. Altered taste preference and loss of limbic-projecting serotonergic neurons in the dorsal raphe nucleus of chronically epileptic rats. Behav. Brain Res., 2016, 297, 28-36. [http://dx.doi.org/10.1016/j.bbr.2015.10.010] [PMID: 26456522]
[10] Li, B.; Wang, L.; Sun, Z.; Zhou, Y.; Shao, D.; Zhao, J.; Song, Y.; Lv, J.; Dong, X.; Liu, C.; Wang, P.; Zhang, X.; Cui, R. The anticonvulsant effects of SR 57227 on pentylenetetrazole seizure in mice. PLoS One, 2014, 9(4), e93158. [http://dx.doi.org/10.1371/journal.pone.0093158] [PMID: 24690630]
[11] a) Blass, B. Sulfonamide Derivatives and Pharmaceutical Applications Thereof., 2015.b) Hoyer, D.; Clarke, D.E.; Fozard, J.R.; Hartig, P.R.; Martin, G.R.; Mylecharane, E.J.; Saxena, P.R.; Humphrey, P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 1994, 46(2), 157-203. [PMID: 79381651]
[12] Ghelipour, T.; Ghasemi, M.; Riazi, K.; Ghaifarpour, M.; Dehpour, A.R. Seizure susceptibility alteration through 5-HT3 receptor: modulation by nitric oxide. Seizure, 2010, 19(1), 17-22. [http://dx.doi.org/10.1016/j.seizure.2009.10.006] [PMID: 19942458]
Levy, F.O.; Holtgreve; 1D and delta opioid receptor loci exhibit significant association to genes for anorexia nervosa in the 1p33 term memory. Antiepilept. Drugs, 2001, 4(24), 515-524. [http://dx.doi.org/10.1046/j.1321-7250.2001.298000.x] [PMID: 11440347]

Bialer, M.; White, H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov., 2010, 9(1), 68-82. [http://dx.doi.org/10.1038/nrd2997] [PMID: 20043029]

Jing, F.; Zhang, J. Metabolic kinetics of 5-hydroxytryptamine and the research targets of functional gastrointestinal disorders. Dig. Dis. Sci., 2014, 59(11), 2642-2648. [http://dx.doi.org/10.1007/s10620-014-3244-x] [PMID: 24916714]

Pedigo, N.W.; Yamamura, H.I.; Nelson, D.L. Discrimination of multiple [3H]-hydroxytryptamine binding sites by the neuropeptide spirogene in rat brain. J. Neurochem., 1981, 36(1), 220-226. [http://dx.doi.org/10.1111/j.1471-4159.1981.tb02397.x] [PMID: 7463047]

Blier, P.; Seletti, B.; Gilbert, F.; Young, S.N.; Benkelfat, C. Serotonin 1A receptor activation and hypothermia in humans: lack of evidence for a presynaptic mediation. Neurropsychopharmacology, 2002, 27(2), 301-308. [http://dx.doi.org/10.1016/S0893-133X(02)00318-4] [PMID: 12093604]

Schoeffter, P.; Hoyer, D. 5-Hydroxytryptamine 5-HT1B and 5-HT1D receptors mediating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolficine and some beta-adrenoceptor antagonists. Naunyn Schmiedebergs Arch. Pharmacol., 1989, 340(3), 285-292. [http://dx.doi.org/10.1007/BF00168512] [PMID: 2572975]

Lin, S.L.; Setya, S.; Johnson-Farley, N.N.; Cowen, D.S. Differential coupling of 5-HT(1) receptors to G proteins of the G(i) family. Br. J. Pharmacol., 2002, 136(7), 1072-1078. [http://dx.doi.org/10.1038/sj.bjp.0704809] [PMID: 12145108]

Bouwknegt, J.A.; Hisen, T.H.; van der Gugten, J.; Maes, R.A.; Hen, R.; Olivier, B. Absence of 5-HT1B receptors is associated with impaired impulse control in male 5-HT1B knockout mice. Biol. Psychiatry, 2001, 49(7), 557-568. [http://dx.doi.org/10.1016/S0006-3223(00)01018-0] [PMID: 11297712]

Meneses, A. Do serotonin-1-F receptors modulate short and long-term memory? Neurobiol. Learn. Mem., 2007, 87(4), 561-572. [http://dx.doi.org/10.1016/j.nlm.2006.12.005] [PMID: 17224282]

Meneses, A. Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: short- and long-term memory. Behav. Brain Res., 2007, 182(1), 81-90. [http://dx.doi.org/10.1016/j.bbr.2007.06.026] [PMID: 17629355]

Bergen, A.W.; van den Bree, M.B.; Yeager, M.; Welch, R.; Gawecki, J.K.; Haque, K.; Bacanu, S.; Berrettini, W.H.; Grice, D.E.; Kiefker, A.D.; Branchek, T.A.; Flaug, M.E. Characterization of L343464 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and neurogenic dual inflammation model of migraine. Life Sci., 1997, 61(21), 2117-2126. [http://dx.doi.org/10.1016/S0022-2891(97)00085-0] [PMID: 9395253]

Amalui, N.; Ramboz, S.; Boschert, U.; Plassat, J.L.; Hen, R. Isolation of a mouse “5HT1E-like” serotonin receptor expressed pre-dominantly in hippocampus. J. Biol. Chem., 1992, 267(28), 19761-19764. [PMID: 1328180]

34 Current Neuropharmacology. 2018. Vol. 16. No. 1

Zhao et al.
5-HT, Receptors: A Potential Therapeutic Target for Epilepsy

Current Neuropharmacology. 2018. Vol. 16. No. 1

[45] Thomas, D.R.; Atkinson, P.J.; Ho, M.; Bromidge, S.M.; Lovell, P.J.; Villani, A.J.; Hagan, J.J.; Middlemiss, D.N.; Price, G.W. [3H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br. J. Pharmacol., 2000, 130(2), 409-417. [http://dx.doi.org/10.1038/sj.bp.3500703] [PMID: 10807680]

[46] Hartig, P.R. Molecular biology of 5-HT receptors. Trends Pharmaco...
Nox4 mediates tumor angiogenesis. *Acta Physiol. (Oxf.), 2015*, 216(4), 435-446. [PMID: 26513738]

[81] Isaac, M. Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs. *Curr. Top. Med. Chem.*, 2005, 5(1), 59-67. [http://dx.doi.org/10.2174/1568026053386980] [PMID: 15638778]

[82] Theodore, W.H. Does serotonin play a role in epilepsy? *Epilepsy Curr.*, 2003, 3(5), 173-177. [http://dx.doi.org/10.1046/j.1535-7597.2003.03508.x] [PMID: 15346169]

[83] Glikmann-Johnston, Y.; Saling, M.M.; Reutens, D.C.; Stout, J.C. Hippocampal 5-HT1A receptor and spatial learning and memory. *Front. Pharmacol.*, 2015, 6, 289. [http://dx.doi.org/10.3389/fphar.2015.00289] [PMID: 26696889]

[84] Haub, S.; Kanuri, G.; Volynets, V.; Brune, T.; Bischoff, S.C.; Berghem, I. Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. *Am. J. Physiol. Gastrointest. Liver Physiol.*, 2010, 298(3), G335-G344. [http://dx.doi.org/10.1152/ajpgi.00088.2009] [PMID: 19713474]

[85] Gutknecht, L.; Popp, S.; Waider, J.; Sommerlandt, F.M.; Göppner, C.; Post, A.; Reif, A.; van den Hove, D.; Strekalova, T.; Schmitt, A.; Colaço, M.B.; Sommer, C.; Palme, R.; Lesch, K.P. Interaction of brain 5-HT synthesis deficiency, chronic stress and sex differentially impact emotional behavior in Tph2 knockout mice. *Psychopharmacology (Berl.), 2015*, 232(14), 2429-2441. [http://dx.doi.org/10.1007/s00213-015-3879-0] [PMID: 25716307]

[86] Viaggi, C.; Gerace, C.; Pardini, C.; Corsini, G.U.; Vaglini, F. Serotonin abnormalities in Engrailed-2 knockout mice: New insight relevant for a model of Autism Spectrum Disorder. *Neurochem. Int.*, 2015, 87, 34-42. [http://dx.doi.org/10.1016/j.neuint.2015.05.004] [PMID: 26002543]

[87] Paciello, N.; Mazza, M.; Mazza, S. Depression in epilepsy: symptom or syndrome? *Clin. Ter.*, 2002, 153(6), 397-402. Depression in epilepsy: symptom or syndrome? [PMID: 12645397]

[88] Kanner, A.M. Management of psychiatric and neurological comorbidities in epilepsy. *Nat. Rev. Neurol.*, 2016, 12(2), 106-116. [http://dx.doi.org/10.1038/nrneurol.2015.243] [PMID: 26782334]

[89] Bagdy, G.; Kecskemeti, V.; Riba, P.; Jakus, R. Serotonin and epilepsy. *J. Neurochem.*, 2007, 100(4), 857-873. [http://dx.doi.org/10.1111/j.1471-4159.2006.04277.x] [PMID: 17212700]

[90] Köhler, S.; Cierpinsky, K.; Kronenberg, G.; Adli, M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. *J. Psychopharmacol. (Oxford), 2016*, 30(1), 13-22. [http://dx.doi.org/10.1177/0269881115609072] [PMID: 26464458]